What is Adocia?
Adocia is a clinical-stage biotechnology company dedicated to creating advanced formulations of established therapeutic proteins and peptides, primarily targeting diabetes and other metabolic disorders. The company boasts a robust pipeline of six clinical-stage injectable treatments for diabetes, positioning it as a leader in this therapeutic area. Adocia has also strategically expanded its development efforts to encompass treatments for obesity and short bowel syndrome, broadening its market reach and therapeutic impact.
How much funding has Adocia raised?
Adocia has raised a total of $27.7M across 3 funding rounds:
Debt
$16.7M
Share Placement
$5.5M
Debt
$5.5M
Debt (2019): $16.7M with participation from IPF Partners
Share Placement (2023): $5.5M, investors not publicly disclosed
Debt (2023): $5.5M supported by Vester Finance
Key Investors in Adocia
IPF Partners
IPF Partners is a specialized alternative financing provider focused on the healthcare sector, offering tailored debt and equity solutions to commercial-stage digital health, biopharma, and late-stage biotech companies. They are known for providing bespoke, low- to non-dilutive debt financing.
Vester Finance
Vester Finance is an entity involved in the company's recent debt financing, indicating participation in the company's capital raising activities.
What's next for Adocia?
With the recent major strategic investment, Adocia is poised to accelerate its clinical development programs and further enhance its innovative formulation technologies. This capital infusion is expected to support the advancement of its diverse portfolio, particularly its differentiated treatments for diabetes, obesity, and short bowel syndrome. The company's focus on leveraging existing therapeutic proteins and peptides with novel delivery systems suggests a strategy aimed at efficient drug development and market entry, positioning Adocia for continued expansion and potential breakthroughs in metabolic disease treatment.
See full Adocia company page
